In short
ART0380 Mesilate is an innovative drug currently being studied in clinical trials for patients with advanced or metastatic solid tumors. This article will provide an overview of the ongoing research, including the drug's potential benefits, safety profile, and its use alone or in combination with other treatments. The trials aim to evaluate ART0380's effectiveness in various cancer types and its potential to improve outcomes for patients with limited treatment options.
At a glance
- Drug Name
- ART0380 Mesilate
- Drug Type
- ATR Kinase Inhibitor
- Administration
- Oral tablet
- Target Conditions
- Advanced or metastatic solid tumors, including ovarian, fallopian tube, peritoneal, endometrial, and colorectal cancers
- Study Phase
- Phase I/IIa
- Study Design
- Open-label, multi-center study
- Treatment Approaches
- Monotherapy and combination therapy with gemcitabine or irinotecan
- Primary Objectives
- Safety, tolerability, pharmacokinetics, and preliminary efficacy
- Key Endpoints
- Incidence of dose-limiting toxicities, adverse events, progression-free survival
- Patient Selection
- Includes patients with specific genetic alterations (e.g., ATM gene alterations) and those resistant to platinum-based therapies
What is ART0380 MESILATE?
ART0380 MESILATE is an investigational drug being developed by Artios Pharma Limited for the treatment of advanced or metastatic solid tumors. It is also known by other names such as IACS-30380 mesilate and ART0380 mesylate. This medication is currently being studied in clinical trials to evaluate its safety and effectiveness in treating various types of cancer.
How does it work?
ART0380 MESILATE is classified as an ATR kinase inhibitor. ATR (Ataxia Telangiectasia and Rad3-related) is a protein that plays a crucial role in DNA damage response. By inhibiting ATR kinase, ART0380 MESILATE may interfere with cancer cells' ability to repair DNA damage, potentially making them more vulnerable to other cancer treatments or causing them to die.
What conditions does it treat?
ART0380 MESILATE is being investigated for the treatment of several types of advanced or metastatic solid tumors, including:
- High-grade serous ovarian cancer
- Fallopian tube cancer
- Primary peritoneal carcinoma
- Endometrial cancer
- Colorectal cancer (CRC)
- Other solid tumors with specific genetic alterations
The drug is particularly being studied in patients whose cancers have alterations in the ATM gene, which may make them more responsive to this treatment.
Clinical Trial Overview
ART0380 MESILATE is currently being evaluated in a Phase I/IIa clinical trial. This study aims to assess the safety, tolerability, and preliminary effectiveness of the drug when given alone or in combination with other cancer treatments. The trial includes several parts:
- Part A: Evaluating ART0380 MESILATE alone and in combination with gemcitabine or irinotecan
- Part B1: Studying ART0380 MESILATE in patients with solid tumors that have ATM gene alterations
- Part B2: Comparing ART0380 MESILATE plus gemcitabine to gemcitabine alone in platinum-resistant ovarian cancer
- Parts B3, B4, and B5: Further evaluating ART0380 MESILATE in various solid tumors
Potential Benefits
While the full benefits of ART0380 MESILATE are still being investigated, the drug shows promise in several areas:
- It may be effective against cancers that have become resistant to other treatments, such as platinum-resistant ovarian cancer.
- It could potentially enhance the effectiveness of other cancer treatments when used in combination.
- It may be particularly beneficial for patients with specific genetic alterations, such as those in the ATM gene.
Administration
ART0380 MESILATE is administered orally in tablet form. The exact dosing schedule and duration of treatment are still being determined through the clinical trials. Patients in the trial may receive the drug alone or in combination with other cancer treatments, depending on their specific situation and the part of the trial they are enrolled in.
Safety Considerations
As with any investigational drug, the full safety profile of ART0380 MESILATE is still being established. The clinical trial is carefully monitoring for any side effects or adverse reactions. Some general considerations for patients participating in the trial include:
- Patients should not be pregnant, breastfeeding, or planning to become pregnant during the study or for several months after.
- Patients should not have certain pre-existing medical conditions, such as significant cardiovascular disease or ongoing interstitial lung disease.
- Patients should inform their doctor about all medications they are taking, as there may be interactions with other drugs.
It's important to note that as an investigational drug, ART0380 MESILATE is not yet approved for general use and is only available through clinical trials. Patients interested in this treatment should discuss their options with their oncologist to determine if they might be eligible for a clinical trial.